Wednesday, 17 July 2019

Tricida readies IPO

06 June 2018 | News

The company says its goal is to slow the progression of chronic kidney disease (CKD) via the treatment of metabolic acidosis (MA).

Singapore-  South San Francisco, CA-based Tricida (TCDA) has filed a preliminary prospectus for a $150M IPO.

The company says its goal is to slow the progression of chronic kidney disease (CKD) via the treatment of metabolic acidosis (MA). Lead candidate is Phase 3-stage TRC101, a non-absorbed polymer designed to treated MA by binding to and removing acid from the GI tract. A U.S. marketing application is on tap for H2 2019.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls